Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,226.71 +4.03 (+0.08%) Dow
39,559.80 +46.96 (+0.12%) Nasdaq
16,386.41 +45.54 (+0.28%) Bitcoin USD
62,796.71 +1,680.57 (+2.75%) CMC Crypto 200
1,295.20 +35.00 (+2.78%)
(NOT.HM)
- GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
- Reuters SG
Deals of the day-Mergers and acquisitions
** Commodities group Glencore is studying an approach for Anglo American, two sources said, a development that could spark a bidding war for the 107-year old mining company. ** U.S. private equity firm Bain Capital is looking at buying some key assets of French tech and software company Atos , reported French paper Les Echos on its website, citing sources.
- Yahoo Finance
CVS stock plunges after earnings numbers one analyst 'did not even believe'
CVS warns it could cede Medicare Advantage market share as reimbursement rates pressure the company.
